159 related articles for article (PubMed ID: 35020746)
1. Remdesivir and dexamethasone as tools to relieve hospital care systems stressed by COVID-19: A modelling study on bed resources and budget impact.
Béraud G; Timsit JF; Leleu H
PLoS One; 2022; 17(1):e0262462. PubMed ID: 35020746
[TBL] [Abstract][Full Text] [Related]
2. Treatment of moderate to severe respiratory COVID-19: a cost-utility analysis.
Congly SE; Varughese RA; Brown CE; Clement FM; Saxinger L
Sci Rep; 2021 Sep; 11(1):17787. PubMed ID: 34493774
[TBL] [Abstract][Full Text] [Related]
3. Remdesivir in combination with dexamethasone for patients hospitalized with COVID-19: A retrospective multicenter study.
Gressens SB; Esnault V; De Castro N; Sellier P; Sene D; Chantelot L; Hervier B; Delaugerre C; Chevret S; Molina JM;
PLoS One; 2022; 17(2):e0262564. PubMed ID: 35176057
[TBL] [Abstract][Full Text] [Related]
4. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
[TBL] [Abstract][Full Text] [Related]
5. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
[TBL] [Abstract][Full Text] [Related]
6. Remdesivir for the treatment of COVID-19.
Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
[TBL] [Abstract][Full Text] [Related]
7. Impact of Remdesivir on the Treatment of COVID-19 During the First Wave in Spain.
Soriano A; Montejano R; Sanz-Moreno J; Figueira JC; Grau S; Güerri-Fernández R; Castro-Gómez A; Pérez-Román I; Hidalgo-Vega Á; González-Domínguez A
Adv Ther; 2021 Jul; 38(7):4057-4069. PubMed ID: 34118007
[TBL] [Abstract][Full Text] [Related]
8. Case report study of the first five COVID-19 patients treated with remdesivir in France.
Dubert M; Visseaux B; Isernia V; Bouadma L; Deconinck L; Patrier J; Wicky PH; Le Pluart D; Kramer L; Rioux C; Le Hingrat Q; Houhou-Fidouh N; Yazdanpanah Y; Ghosn J; Lescure FX
Int J Infect Dis; 2020 Sep; 98():290-293. PubMed ID: 32619764
[TBL] [Abstract][Full Text] [Related]
9. Missed Opportunities on Emergency Remdesivir Use.
Sarpatwari A; Kaltenboeck A; Kesselheim AS
JAMA; 2020 Jul; 324(4):331-332. PubMed ID: 32579163
[No Abstract] [Full Text] [Related]
10. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status.
Antinori S; Cossu MV; Ridolfo AL; Rech R; Bonazzetti C; Pagani G; Gubertini G; Coen M; Magni C; Castelli A; Borghi B; Colombo R; Giorgi R; Angeli E; Mileto D; Milazzo L; Vimercati S; Pellicciotta M; Corbellino M; Torre A; Rusconi S; Oreni L; Gismondo MR; Giacomelli A; Meroni L; Rizzardini G; Galli M
Pharmacol Res; 2020 Aug; 158():104899. PubMed ID: 32407959
[TBL] [Abstract][Full Text] [Related]
11. Remdesivir for COVID-19 in Europe: will it provide value for money?
Dal-Ré R; Banzi R; Georgin-Lavialle S; Porcher R; Sofat R; Zeitlinger M; Rosendaal FR
Lancet Respir Med; 2021 Feb; 9(2):127-128. PubMed ID: 33341157
[No Abstract] [Full Text] [Related]
12. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
[TBL] [Abstract][Full Text] [Related]
13. Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review.
Cantini F; Goletti D; Petrone L; Najafi Fard S; Niccoli L; Foti R
Drugs; 2020 Dec; 80(18):1929-1946. PubMed ID: 33068263
[TBL] [Abstract][Full Text] [Related]
14. Use of Hydroxychloroquine, Remdesivir, and Dexamethasone Among Adults Hospitalized With COVID-19 in the United States : A Retrospective Cohort Study.
Mehta HB; An H; Andersen KM; Mansour O; Madhira V; Rashidi ES; Bates B; Setoguchi S; Joseph C; Kocis PT; Moffitt R; Bennett TD; Chute CG; Garibaldi BT; Alexander GC;
Ann Intern Med; 2021 Oct; 174(10):1395-1403. PubMed ID: 34399060
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 treatment combinations and associations with mortality in a large multi-site healthcare system.
Coppock D; Baram M; Chang AM; Henwood P; Kubey A; Summer R; Zurlo J; Li M; Hess B
PLoS One; 2021; 16(6):e0252591. PubMed ID: 34115801
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios.
Jiang Y; Cai D; Chen D; Jiang S; Si L; Wu J
Br J Clin Pharmacol; 2021 Nov; 87(11):4386-4396. PubMed ID: 33855727
[TBL] [Abstract][Full Text] [Related]
17. Real-life use of remdesivir in hospitalized patients with COVID-19.
Garcia-Vidal C; Meira F; Cózar-Llistó A; Dueñas G; Puerta-Alcalde P; Garcia-Pouton N; Chumbita M; Cardozo C; Hernandez-Meneses M; Alonso-Navarro R; Rico V; Agüero D; Bodro M; Morata L; Jordan C; Lopera C; Ambrosioni J; Segui F; Grafia N; Castro P; García F; Mensa J; Martínez JA; Sanjuan G; Soriano A;
Rev Esp Quimioter; 2021 Apr; 34(2):136-140. PubMed ID: 33675220
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.
Kalil AC; Mehta AK; Patterson TF; Erdmann N; Gomez CA; Jain MK; Wolfe CR; Ruiz-Palacios GM; Kline S; Regalado Pineda J; Luetkemeyer AF; Harkins MS; Jackson PEH; Iovine NM; Tapson VF; Oh MD; Whitaker JA; Mularski RA; Paules CI; Ince D; Takasaki J; Sweeney DA; Sandkovsky U; Wyles DL; Hohmann E; Grimes KA; Grossberg R; Laguio-Vila M; Lambert AA; Lopez de Castilla D; Kim E; Larson L; Wan CR; Traenkner JJ; Ponce PO; Patterson JE; Goepfert PA; Sofarelli TA; Mocherla S; Ko ER; Ponce de Leon A; Doernberg SB; Atmar RL; Maves RC; Dangond F; Ferreira J; Green M; Makowski M; Bonnett T; Beresnev T; Ghazaryan V; Dempsey W; Nayak SU; Dodd L; Tomashek KM; Beigel JH;
Lancet Respir Med; 2021 Dec; 9(12):1365-1376. PubMed ID: 34672949
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement.
Best JH; Kong AM; Kaplan-Lewis E; Brawley OW; Baden R; Zazzali JL; Miller KS; Loveless J; Jariwala-Parikh K; Mohan SV
J Med Virol; 2021 Sep; 93(9):5367-5375. PubMed ID: 33913536
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
Barratt-Due A; Olsen IC; Nezvalova-Henriksen K; Kåsine T; Lund-Johansen F; Hoel H; Holten AR; Tveita A; Mathiessen A; Haugli M; Eiken R; Kildal AB; Berg Å; Johannessen A; Heggelund L; Dahl TB; Skåra KH; Mielnik P; Le LAK; Thoresen L; Ernst G; Hoff DAL; Skudal H; Kittang BR; Olsen RB; Tholin B; Ystrøm CM; Skei NV; Tran T; Dudman S; Andersen JT; Hannula R; Dalgard O; Finbråten AK; Tonby K; Blomberg B; Aballi S; Fladeby C; Steffensen A; Müller F; Dyrhol-Riise AM; Trøseid M; Aukrust P;
Ann Intern Med; 2021 Sep; 174(9):1261-1269. PubMed ID: 34251903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
